NCT01585168View on ClinicalTrials.gov

Functional Neuroimaging of Alcoholism Vulnerability (PIT)

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Healthy
Interventions
DRUG

Memantine

Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.

DRUG

Placebo

Identically appearing sugar pill, given orally

Trial Locations (1)

06106

Olin Neuropsychiatry Research Center at the Institute of Living, Hartford Hospital, Hartford

All Listed Sponsors
lead

Yale University

OTHER

NCT01585168 - Functional Neuroimaging of Alcoholism Vulnerability (PIT) | Biotech Hunter | Biotech Hunter